# To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

> **NCT04914377** · PHASE2 · COMPLETED · sponsor: **Novatek Pharmaceuticals** · enrollment: 55 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** TQ Formula/Tab

## Key facts

- **NCT ID:** NCT04914377
- **Lead sponsor:** Novatek Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-08
- **Primary completion:** 2021-12-16
- **Final completion:** 2022-01-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04914377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04914377, "To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04914377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*